ZA200306120B - Hormone replacement therapy method and its administration form. - Google Patents
Hormone replacement therapy method and its administration form. Download PDFInfo
- Publication number
- ZA200306120B ZA200306120B ZA200306120A ZA200306120A ZA200306120B ZA 200306120 B ZA200306120 B ZA 200306120B ZA 200306120 A ZA200306120 A ZA 200306120A ZA 200306120 A ZA200306120 A ZA 200306120A ZA 200306120 B ZA200306120 B ZA 200306120B
- Authority
- ZA
- South Africa
- Prior art keywords
- ingestion
- hormone
- daily units
- administration
- phase
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 24
- 238000002657 hormone replacement therapy Methods 0.000 title claims description 21
- 230000037406 food intake Effects 0.000 claims description 220
- 229940088597 hormone Drugs 0.000 claims description 117
- 239000005556 hormone Substances 0.000 claims description 117
- 229940011871 estrogen Drugs 0.000 claims description 48
- 239000000262 estrogen Substances 0.000 claims description 48
- 239000000583 progesterone congener Substances 0.000 claims description 39
- 238000010586 diagram Methods 0.000 claims description 34
- 230000007704 transition Effects 0.000 claims description 30
- 239000000902 placebo Substances 0.000 claims description 26
- 238000004806 packaging method and process Methods 0.000 claims description 10
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000002354 daily effect Effects 0.000 claims 48
- 230000003203 everyday effect Effects 0.000 claims 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 11
- 229960000978 cyproterone acetate Drugs 0.000 description 11
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 11
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 11
- 229960004845 drospirenone Drugs 0.000 description 11
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 11
- 229960004766 estradiol valerate Drugs 0.000 description 11
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 10
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 7
- 229960004400 levonorgestrel Drugs 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 230000027758 ovulation cycle Effects 0.000 description 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940053934 norethindrone Drugs 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 2
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
- 206010047998 Withdrawal bleed Diseases 0.000 description 2
- 229960001616 chlormadinone acetate Drugs 0.000 description 2
- 229960004976 desogestrel Drugs 0.000 description 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 2
- 229960003309 dienogest Drugs 0.000 description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 229960001910 lynestrenol Drugs 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 229960001652 norethindrone acetate Drugs 0.000 description 2
- 229960000417 norgestimate Drugs 0.000 description 2
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- GVBPNTAYETYXBE-WAJSLEGFSA-N S(N)(O)(=O)=O.[C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 Chemical compound S(N)(O)(=O)=O.[C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 GVBPNTAYETYXBE-WAJSLEGFSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10100911A DE10100911A1 (de) | 2001-01-11 | 2001-01-11 | Verfahren zur Hormonersatztherapie und dessen Darreichungsform |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200306120B true ZA200306120B (en) | 2004-09-08 |
Family
ID=7670195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200306120A ZA200306120B (en) | 2001-01-11 | 2003-08-07 | Hormone replacement therapy method and its administration form. |
Country Status (21)
Country | Link |
---|---|
US (1) | US7871994B2 (pt) |
EP (1) | EP1372665B1 (pt) |
JP (1) | JP2004525883A (pt) |
AR (1) | AR033413A1 (pt) |
AT (1) | ATE348620T1 (pt) |
AU (1) | AU2007202118A1 (pt) |
BR (1) | BR0206361A (pt) |
CA (1) | CA2433656A1 (pt) |
CY (1) | CY1106374T1 (pt) |
DE (2) | DE10100911A1 (pt) |
DK (1) | DK1372665T3 (pt) |
ES (1) | ES2278896T3 (pt) |
IL (1) | IL156655A0 (pt) |
MX (1) | MXPA03006157A (pt) |
NO (1) | NO20033155L (pt) |
NZ (1) | NZ539581A (pt) |
PE (1) | PE20020795A1 (pt) |
PT (1) | PT1372665E (pt) |
UY (1) | UY27117A1 (pt) |
WO (1) | WO2002055086A2 (pt) |
ZA (1) | ZA200306120B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2495330A1 (en) * | 2002-08-28 | 2004-03-11 | Robert Casper | Estrogen replacement regimen |
WO2004041288A1 (en) * | 2002-11-05 | 2004-05-21 | Schering Aktiengesellschaft | Hormone replacement therapy with drospirenone |
US7786101B2 (en) | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
PT1558265E (pt) * | 2002-11-05 | 2010-03-22 | Bayer Schering Pharma Ag | Utilização da drospirenona para o tratamento da hipertensão |
ES2482104T3 (es) | 2003-09-29 | 2014-08-01 | Novo Nordisk Femcare Ag | Formulaciones HRT |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
DE4224534A1 (de) | 1992-07-24 | 1994-01-27 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
DE4405590C1 (de) | 1994-02-22 | 1995-07-20 | Hesch Rolf Dieter Prof Dr Med | Mittel zur postmenopausalen Hormonbehandlung |
DE4405591C1 (de) | 1994-02-22 | 1995-07-20 | Hesch Rolf Dieter Prof Dr Med | Mittel zur postmenopausalen Hormonsubstitution |
DE19513662A1 (de) | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
DE19539233A1 (de) | 1995-10-21 | 1997-04-24 | Klaus Dr Med Umbreit | Oral einzunehmendes ovulationshemmendes Mittel |
-
2001
- 2001-01-11 DE DE10100911A patent/DE10100911A1/de not_active Ceased
-
2002
- 2002-01-08 BR BR0206361-1A patent/BR0206361A/pt not_active IP Right Cessation
- 2002-01-08 MX MXPA03006157A patent/MXPA03006157A/es unknown
- 2002-01-08 WO PCT/EP2002/000089 patent/WO2002055086A2/en active IP Right Grant
- 2002-01-08 NZ NZ539581A patent/NZ539581A/en unknown
- 2002-01-08 CA CA002433656A patent/CA2433656A1/en not_active Abandoned
- 2002-01-08 DE DE60216899T patent/DE60216899T2/de not_active Expired - Lifetime
- 2002-01-08 DK DK02700196T patent/DK1372665T3/da active
- 2002-01-08 US US10/466,197 patent/US7871994B2/en not_active Expired - Fee Related
- 2002-01-08 EP EP02700196A patent/EP1372665B1/en not_active Expired - Lifetime
- 2002-01-08 PT PT02700196T patent/PT1372665E/pt unknown
- 2002-01-08 ES ES02700196T patent/ES2278896T3/es not_active Expired - Lifetime
- 2002-01-08 JP JP2002555820A patent/JP2004525883A/ja active Pending
- 2002-01-08 AT AT02700196T patent/ATE348620T1/de not_active IP Right Cessation
- 2002-01-08 IL IL15665502A patent/IL156655A0/xx unknown
- 2002-01-09 UY UY27117A patent/UY27117A1/es not_active Application Discontinuation
- 2002-01-10 PE PE2002000009A patent/PE20020795A1/es not_active Application Discontinuation
- 2002-01-11 AR ARP020100080A patent/AR033413A1/es unknown
-
2003
- 2003-07-10 NO NO20033155A patent/NO20033155L/no not_active Application Discontinuation
- 2003-08-07 ZA ZA200306120A patent/ZA200306120B/en unknown
-
2007
- 2007-03-13 CY CY20071100350T patent/CY1106374T1/el unknown
- 2007-05-11 AU AU2007202118A patent/AU2007202118A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2433656A1 (en) | 2002-07-18 |
BR0206361A (pt) | 2004-02-17 |
IL156655A0 (en) | 2004-01-04 |
DE10100911A1 (de) | 2002-08-01 |
PT1372665E (pt) | 2007-03-30 |
DE60216899D1 (de) | 2007-02-01 |
AR033413A1 (es) | 2003-12-17 |
NZ539581A (en) | 2007-07-27 |
MXPA03006157A (es) | 2003-09-16 |
CY1106374T1 (el) | 2011-10-12 |
DK1372665T3 (da) | 2007-04-30 |
UY27117A1 (es) | 2002-07-31 |
NO20033155D0 (no) | 2003-07-10 |
EP1372665B1 (en) | 2006-12-20 |
EP1372665A2 (en) | 2004-01-02 |
ATE348620T1 (de) | 2007-01-15 |
WO2002055086A2 (en) | 2002-07-18 |
DE60216899T2 (de) | 2007-10-25 |
AU2007202118A1 (en) | 2007-05-31 |
NO20033155L (no) | 2003-09-10 |
US20040106586A1 (en) | 2004-06-03 |
US7871994B2 (en) | 2011-01-18 |
WO2002055086A3 (en) | 2003-10-16 |
JP2004525883A (ja) | 2004-08-26 |
ES2278896T3 (es) | 2007-08-16 |
PE20020795A1 (es) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2420292C (en) | Contraception process and administration form for the same | |
AU616208B2 (en) | Compounds having antiprogestational and anti-estrogenic activities for induction of labor and for termination of pregnancy, as well as for the treatment of gynaecological disorders | |
AU2001284052A1 (en) | Contraception process and administration form for the same | |
AU2007202118A1 (en) | Hormone replacement therapy method and its administration form | |
HU229251B1 (en) | Triphasic oral contraceptive | |
CN104248639A (zh) | 延长的雌激素定量给药避孕疗法 | |
JP2007535519A5 (pt) | ||
DK162474B (da) | Fler-fasesekvenspraeparat af kombinationstypen til oral svangerskabsforebyggelse | |
London et al. | Rationale for eliminating the hormone-free interval in modern oral contraceptives | |
Cedars | Triphasic oral contraceptives: review and comparison of various regimens | |
AU2002233304A1 (en) | Hormone replacement therapy method and its administration form | |
CN1313095C (zh) | 低剂量口服避孕药启动试剂盒 | |
JP2008527018A (ja) | 避妊用医薬製剤 | |
US20080280861A1 (en) | Method of Female Contraception and a Kit For Use Therein |